Banco BTG Pactual S.A. Sells 4,955 Shares of Insmed, Inc. $INSM

Key Points

• Banco BTG Pactual S.A. reduced its holdings in Insmed, Inc. by 60.1%, selling 4,955 shares and holding 3,285 shares valued at $251,000 at the end of the recent quarter.
• Several institutional investors, including Mariner LLC and MetLife Investment Management LLC, increased their stakes in Insmed during the fourth quarter, indicating growing interest in the biopharmaceutical company.
• Insmed's recent quarterly earnings report revealed a loss of ($1.70) per share, missing estimates but showing an 18.9% revenue increase year-over-year to $107.42 million.

Banco BTG Pactual S.A. trimmed its holdings in shares of Insmed, Inc. (NASDAQ:INSM - Free Report) by 60.1% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,285 shares of the biopharmaceutical company's stock after selling 4,955 shares during the period. Banco BTG Pactual S.A.'s holdings in Insmed were worth $251,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Renaissance Technologies LLC acquired a new position in Insmed during the fourth quarter valued at approximately $1,746,000. Mariner LLC increased its position in shares of Insmed by 23.4% during the 4th quarter. Mariner LLC now owns 30,788 shares of the biopharmaceutical company's stock worth $2,126,000 after purchasing an additional 5,844 shares during the last quarter. Jump Financial LLC bought a new stake in shares of Insmed during the 4th quarter worth approximately $230,000. CANADA LIFE ASSURANCE Co raised its stake in shares of Insmed by 4.1% during the 4th quarter. CANADA LIFE ASSURANCE Co now owns 39,379 shares of the biopharmaceutical company's stock worth $2,717,000 after purchasing an additional 1,568 shares in the last quarter. Finally, MetLife Investment Management LLC boosted its holdings in shares of Insmed by 15.4% in the 4th quarter. MetLife Investment Management LLC now owns 103,429 shares of the biopharmaceutical company's stock valued at $7,141,000 after buying an additional 13,807 shares during the last quarter.

Insider Transactions at Insmed

In other Insmed news, insider Michael Alexander Smith sold 933 shares of the company's stock in a transaction on Tuesday, July 15th. The stock was sold at an average price of $102.51, for a total value of $95,641.83. Following the transaction, the insider directly owned 66,394 shares of the company's stock, valued at $6,806,048.94. This represents a 1.39% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO William Lewis sold 6,865 shares of Insmed stock in a transaction on Monday, August 18th. The stock was sold at an average price of $128.40, for a total value of $881,466.00. Following the sale, the chief executive officer directly owned 233,924 shares of the company's stock, valued at $30,035,841.60. This represents a 2.85% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 504,694 shares of company stock valued at $48,660,104. Company insiders own 3.00% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Leerink Partners boosted their target price on shares of Insmed from $100.00 to $115.00 and gave the stock an "outperform" rating in a report on Tuesday, June 10th. Royal Bank Of Canada lifted their price objective on shares of Insmed from $108.00 to $120.00 and gave the company an "outperform" rating in a research report on Friday, August 8th. Mizuho boosted their price objective on shares of Insmed from $130.00 to $165.00 and gave the stock an "outperform" rating in a research note on Wednesday, August 13th. Citigroup upgraded shares of Insmed to a "buy" rating in a research note on Tuesday, June 10th. Finally, Wells Fargo & Company boosted their price target on Insmed from $130.00 to $140.00 and gave the stock an "overweight" rating in a research report on Tuesday, August 12th. Sixteen analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $131.29.

Insmed Stock Performance

Shares of INSM stock opened at $129.45 on Thursday. Insmed, Inc. has a 52 week low of $60.40 and a 52 week high of $130.13. The company has a market capitalization of $27.36 billion, a price-to-earnings ratio of -22.67 and a beta of 0.95. The company has a 50-day simple moving average of $106.10 and a 200 day simple moving average of $84.93. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.33 and a current ratio of 6.68.

Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, missing the consensus estimate of ($1.30) by ($0.40). Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The company had revenue of $107.42 million during the quarter, compared to the consensus estimate of $104.06 million. During the same period in the prior year, the company earned ($1.94) earnings per share. The firm's revenue was up 18.9% compared to the same quarter last year. Insmed has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that Insmed, Inc. will post -4.56 earnings per share for the current year.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.